Industry Odisha Bureau, Sep 09: A government sub-committee has recommended retaining India’s doorstep delivery rule. Withdrawing the 2020 notification could hurt several patient groups. The panel instead favoured stronger enforcement of existing safeguards. Patient access was a central consideration in that decision.
The framework, known as GSR 220(E), permits doorstep medicine delivery. It operates under specific conditions set in 2020. A government sub-committee recently reviewed whether to withdraw it. The rule allows delivery under prescribed regulatory conditions.
The panel concluded that scrapping GSR 220(E) was not advisable. It said the rule continued serving an important purpose. This benefit outweighed concerns raised during the review.
Elderly patients and those with chronic conditions were highlighted. The panel said many rely on doorstep delivery regularly. Withdrawal could leave them without practical access to medicines. The panel said withdrawal risked disrupting regular medication access.
Residents of rural and remote areas were also considered. The panel noted nuclear households and single parents too. These groups may depend more on home delivery services. The framework offers an additional channel for medicine access.
The All India Organisation of Chemists and Druggists sought withdrawal. It argued digital platforms misused the notification’s provisions. The association raised these concerns with the government directly. That association represents chemists and druggists nationwide.
Its concerns involved Rule 65(e) of the Drugs Rules, 1945. That rule requires medicine sales against original prescriptions. The association alleged some digital platforms bypassed this requirement. Swiggy was among platforms referenced in those concerns. The claims concerned prescription verification during doorstep deliveries.
The Drugs Technical Advisory Board first discussed this in April 2025. It recommended forming a sub-committee to examine the matter. That sub-committee submitted its report this past May. No committee membership details were disclosed publicly.
Rather than scrapping the rule, the panel suggested stricter enforcement. It wants better regulation of medicine sales through digital platforms. It emphasized implementation over eliminating the existing framework.
The panel called for preventing irregular or unauthorised online sales. It wants no sales to occur without valid prescriptions. Digital platforms should follow all procedures under the notification. These measures aim to close existing compliance gaps.
The decision affects pharmaceutical retail and digital medicine distribution alike. Doorstep delivery has become an important channel for many patients. Regulatory clarity matters for platforms and traditional chemists both. The framework’s future depends on how strictly it’s enforced.
The panel’s approach tries to balance access and compliance. It treats accessibility and prescription safeguards as compatible goals. Neither goal was treated as more important than the other.
India’s medicine-delivery framework now faces a clear enforcement task. Regulators must ensure access continues alongside strict prescription checks. That balance will shape how digital platforms operate going forward. The panel’s recommendation still awaits formal government action.
